Aastrom Biosciences begins study of new stem cell transplant procedure in leukemia patients.
As the use of cord blood stem cells to treat patients with leukemia and other diseases increases, Aastrom says there is concern about the comparatively small quantity of transplant cells available from standard cord blood cell collection procedures. The company says the Aastrom Replicell System, along with the CB-II Therapy Kit, has the potential to improve the availability, and hopefully the effectiveness, of cord blood stem cell transplants by increasing the amount of key therapeutic cells 10-fold.
An estimated 60,000 people are diagnosed with leukemia each year, and Aastrom believes about 35,000 are potential candidates for cord blood-derived stem cell transplants if a large enough cell dose is available.
Contact: Lisa Fern - (734) 930-5777, ext. 353
|Printer friendly Cite/link Email Feedback|
|Comment:||Aastrom Biosciences begins study of new stem cell transplant procedure in leukemia patients.|
|Article Type:||Brief Article|
|Date:||Nov 30, 2000|
|Previous Article:||Regeneration Technologies distributing new sports medicine allografts designed to cut operating room time.|
|Next Article:||Orchid BioSciences launches innovative Web site to facilitate bone marrow transplant testing.|